ImCheck to Present Early Patient Response Data from the EVICTION Trial at the ESMO Congress 2021
ImCheck Therapeutics today announced that it will present updated clinical data from the ongoing EVICTION Phase I/IIa…
ImCheck Publishes Seminal Paper in Cell Reports Elucidating How Butyrophilins Activate Vγ9Vδ2 T cell Function Against Tumor Cells
- First published study showing the role and sequential interaction of butyrophilin subtypes in the induction of…
ImCheck Announces Initiation of U.S. Enrollment in Phase I/IIa EVICTION Trial for ICT01
EVICTION is a multi-center trial evaluating Butyrophilin 3A-targeted activation of the anti-tumor immune response of…
ImCheck Therapeutics Appoints Dr. Loui Madakamutil, Noted Expert in Immunology and Autoimmune Diseases, as Chief Scientific Officer
ImCheck Therapeutics today announced the appointment of Loui Madakamutil, PhD, as Chief Scientific Officer (CSO). Dr.…
Clinical Data with ImCheck’s ICT01 to be Presented at AACR: Positive Results Observed on Safety, Activation of Gamma 9 Delta 2 T Cells and Anti-tumor Immune Response
ICT01 activates γ9δ2 T cells that rapidly migrate out of the circulation and secrete IFNγ and TNFα leading to an…
ImCheck to Present Data Demonstrating Activation of the Anti-Tumor Immune Response of Gamma9 Delta2 T Cells in Cancer Patients from the Ongoing Phase I/IIa EVICTION Trial at the AACR Annual Meeting 2021
ImCheck Therapeutics today announced that it will present clinical data from the ongoing EVICTION Phase I/IIa clinical…
For a second year, ImCheck has been selected by the French Tech as one of the top 120 French startups and of the 9 biotech companies developing innovative therapies
Repeating its selection in 2020, ImCheck has again been recognized as one of the top 120 French startups based on…
ImCheck Presents at SITC First Clinical Demonstration of Gamma Delta T Cell Activation and Tumor Infiltration with Positive Safety for ICT01
Preliminary EVICTION Phase I/IIa trial data shows butyrophilin-targeted mAb ICT01’s dose-dependent and specific…
ImCheck Announces Four ICT01 Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting
Marseille, France, October 14, 2020 – ImCheck Therapeutics today announced the acceptance of four clinical and…
ImCheck Announces Investment by BB Pureos Bioventures to Close Series B Fundraising with Total of €54 million ($64 million)
ImCheck Therapeutics today announced that it has secured an additional €6 million ($7.1 million) from BB Pureos…
ImCheck Achieves Initial Positive Independent Safety Review and Initiates Next Stage of Phase I/IIa EVICTION Trial for ICT01 - Company Receives FDA Approval for US IND
ImCheck Therapeutics announced today that the independent Safety Review Committee for the EVICTION Phase I/II clinical…
ImCheck Therapeutics Appoints Claude Knopf as Chief Business Officer
First hire in the US will support growing global business development activities
Marseille, France, July 9, 2020 –…
HalioDx to Characterize the Immune Contexture of Patients Enrolled in ImCheck’s EVICTION Phase 1/2 Clinical Trial
HalioDx’s immunoscoring technologies to characterize patients treated with ImCheck’s investigational first-in-class…
First Patient Dosed in EVICTION Trial Evaluating ImCheck’s Lead Anti-Cancer Drug, ICT01: A Novel Gamma Delta T Cell-Activating Immunotherapy
-- First-in-human, international, multi-center trial to test Butyrophylin 3A-targeted antibody in advanced solid and…
ImCheck Therapeutics Expands Leadership Team with Appointment of Hans Henrik Chrois Christensen as Chief Financial Officer and Chief Operating Officer
-- Mr. Christensen adds financial, strategic and corporate development expertise to the ImCheck team --
Marseille,…
ImCheck Therapeutics is one of the 8 young French biotechs selected in the French Tech 120 program!
The French Tech revealed on January 20th the 83 most promising French startups for 2020 and ImCheck Therapeutics is…
ImCheck Raises $53 Million Series B to Advance Clinical Pipeline of Novel Gamma Delta T-Cell-Focused Antibodies for Cancer and Autoimmune Diseases
-- Bpifrance and Pfizer Ventures co-led international investor syndicate --
Marseille, France, December 04, 2019, 6:45…
ImCheck Therapeutics awarded €2 million from Bpifrance to advance its first-in-class immunotherapy program into the clinic
Bpifrance views ImCheck’s projects as unique and well-positioned
ImCheck Therapeutics, a biotech company on the cutting…
ImCheck Therapeutics appoints Paul Frohna MD, PhD, PharmD, as Chief Medical Officer
Paul Frohna brings over 15 years of experience in translational medicine and clinical and regulatory strategy
ImCheck…
The French Région Sud and the European Union provide grant funding to Imcheck Therapeutics and its development of a new generation of cancer treatments
Through a 717 K€ grant co-financed by the Région Sud and the European Union under the ERDF, ImCheck has received…